tradingkey.logo
搜尋

Evolus Inc

EOLS
添加自選
6.900USD
+0.160+2.37%
收盤 07/02, 13:00美東報價延遲15分鐘
454.29M總市值
虧損本益比TTM

Evolus Inc

6.900
+0.160+2.37%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.37%

5天

-3.23%

1月

+4.55%

6月

+2.68%

今年開始到現在

+3.76%

1年

-25.57%

關鍵數據
6.770今開
6.905最高
534.87K成交量
虧損本益比TTM
28.01本益比動
--股利TTM
0.81%換手率
6.740昨收
6.695最低
2.45M成交額
虧損本益比靜
-15.78市淨率
0.00%股息率 TTM
-20.01%ROA
10.62052週最高
1.01量比
-50.42M淨利潤
65.84M總股本
-0.6682每股盈餘TTM
1.34Beta
-18729.61%ROE
3.86052週最低
3.12%振幅
64.27%毛利率
454.29M總市值
0.65回報/風險
3.27%風險率

TradingKey Evolus Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Evolus Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名46/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為14.67。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Evolus Inc評分

相關信息

行業排名
46 / 157
全市場排名
104 / 4565
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Evolus Inc亮點

亮點風險
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
業績高增長
公司營業收入穩步增長,連續3年增長47.05%
估值合理
公司最新PE估值-10.33,處於3年歷史合理位
機構減倉
最新機構持股50.03M股,環比減少24.26%

分析師目標

基於 7 分析師
買入
評級
14.667
目標均價
+117.61%
漲幅空間

Evolus Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Evolus Inc簡介

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
公司代碼EOLS
公司Evolus Inc
CEOMoatazedi (David)
網址https://www.evolus.com/

常見問題

Evolus Inc(EOLS)的當前股價是多少?

Evolus Inc(EOLS)的當前股價是 6.90。

Evolus Inc 的股票代碼是什麼?

Evolus Inc的股票代碼是EOLS。

Evolus Inc股票的52週最高點是多少?

Evolus Inc股票的52週最高點是10.62。

Evolus Inc股票的52週最低點是多少?

Evolus Inc股票的52週最低點是3.86。

Evolus Inc的市值是多少?

Evolus Inc的市值是454.29M。

現在Evolus Inc(EOLS)的股票是買入、持有還是賣出?

根據分析師評級,Evolus Inc(EOLS)的總體評級為買入,目標價格為14.67。

Evolus Inc(EOLS)股票的每股收益(EPS TTM)是多少

Evolus Inc(EOLS)股票的每股收益(EPS TTM)是-0.80。